Evaluation of MP-101 on Biomarkers in Patients with Huntington's, Alzheimer's, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis

The primary objective of this clinical trial is to evaluate the effects of the investigational drug **MP-101** on laboratory markers associated with **Huntington’s Disease (HD)**, **Amyotrophic Lateral Sclerosis (ALS)**, **Multiple Sclerosis (MS)**, and **Alzheimer’s Disease (AD)**. Understanding these effects is clinically relevant as it may provide insights into the potential therapeutic benefits of MP-101 in modifying disease progression or symptoms in these neurodegenerative conditions.

The clinical trial involves participants diagnosed with **Huntington’s Disease**, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial population is noted to include a vulnerable population, although specific details regarding the selection process or lifestyle considerations such as diet or physical activity are not provided. The sponsor has not disclosed the total number of participants involved in the study.

The clinical trial is designed to evaluate the effects of an investigational drug, MP-101, on laboratory signs in patients diagnosed with **Huntington's Disease**, **Alzheimer's Disease**, **Amyotrophic Lateral Sclerosis**, and **Multiple Sclerosis**. This study is a Phase 3 trial, which is randomized, double-blind, and controlled to ensure the reliability and validity of the results. The trial is expected to commence recruitment on December 1, 2023, and is projected to conclude by November 1, 2024, making the overall duration approximately 11 months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomly assigned to either the investigational drug group or a control group. Throughout the trial, participants will attend regular follow-up visits to monitor their health status, adherence to the study protocol, and any potential side effects. These visits are crucial for collecting data on the drug's efficacy and safety. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the drug's impact.

The expected length of participant involvement is contingent upon the trial's schedule, with each participant likely to be involved for the full duration of the study unless specific conditions necessitate early termination. Such conditions may include adverse reactions to the investigational drug, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial's design and procedures are structured to ensure the collection of robust data while prioritizing participant safety and adherence to ethical standards.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included in the trial documentation.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on December 1, 2023, with an estimated completion date of November 1, 2024. The efficacy of the intervention will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters at predetermined timepoints throughout the study duration. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy assessments.